#tecovirimat — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #tecovirimat, aggregated by home.social.
-
[Correspondence] #Mpox virus in #human #breastmilk and #tecovirimat pharmacokinetics: implications for #postnatal #transmission https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00138-6/fulltext?rss=yes
-
#Antiviral activity of #tecovirimat against #monkeypox virus clades 1a, 1b, 2a, and 2b, https://etidiohnew.blogspot.com/2025/01/antiviral-activity-of-tecovirimat.html
-
#US #NIH #Study Finds #Tecovirimat Was Safe but Did Not Improve #Mpox Resolution or #Pain, https://www.nih.gov/news-events/news-releases/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain
#Antiviral drug tecovirimat did not reduce time to lesion #resolution or have an effect on pain among adults with mild to moderate clade II mpox & a low risk of developing severe disease, according to an interim data analysis from international clinical trial called the Study of Tecovirimat for Mpox (STOMP). There were no safety concerns associated with tecovirimat.
-
Source: Emerging Infectious Diseases Journal, https://wwwnc.cdc.gov/eid/article/30/11/24-1331_article
Abstract
We report a case of persistent disseminated mpox evolving over >6 months in an HIV/hepatitis B virus co-infected patient in France who had <200 CD4+ cells/mm3, pulmonary and hepatic necrotic lesions, persistent viremia, and nasopharyngeal excretion. Clinical outcome was favorable after 90 days of tecovirimat treatment and administration of human vaccinia immunoglobulins.____
#abstract #antivirals #france #hepatitisB #HIVAIDS #mpox #research #tecovirimat
-
Notes from the Field: #Mpox #Cluster Caused by #Tecovirimat – #Resistant Monkeypox Virus – Five States, October 2023-February 2024
Source: US National Library of Medicine, AbstractThe antiviral drug tecovirimat* has been used extensively to treat U.S. mpox cases since the start of a global outbreak in 2022. Mutations in the mpox viral protein target (F13 or VP37) that occur during treatment can result in resistance to tecovirimat† (1,2). CDC and public health partners…
-
#Tecovirimat Use under Expanded Access to Treat #Mpox in #USA, 2022–2023, NEJM Evidence: https://evidence.nejm.org/doi/10.1056/EVIDoa2400189
Tecovirimat was used extensively. The returned EA-IND data suggest that life-threatening or protracted #infections occurred in persons who were severely immunocompromised. #SAEs were not commonly reported. The EA-IND data are not definitive; controlled clinical trial data are essential to elucidating if and how tecovirimat should be used.
-
#Mpox #outbreak — #tecovirimat #resistance, #management approaches, and #challenges in #HIV-endemic regions, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00591-7/fulltext?rss=yes
... while concentrating our efforts on responding to the current outbreak and gaining better insight into shifting MPXV biology in the human host, ensuring access to antivirals—particularly #ART—and comprehensive HIV care remains crucial.
-
Mpox Disease: The Antiviral Tecovirimat (TPOXX) Found Ineffective in Clinical Trial
The monkeypox virus (MPXV), called so because of its first discovery in monkeys kept in research facility in Denmark, is closely related to variola...........
#antiviral #AntiviralDrug #DRCongo #monkeypox #monkeypoxvirus #Mpox #MPXV #Tecovirimat
Umesh Prasad -
#Antiviral #tecovirimat is safe but {was ineffective in} clade I #mpox #resolution in #DRC, US #NIH: https://www.nih.gov/news-events/news-releases/antiviral-tecovirimat-safe-did-not-improve-clade-i-mpox-resolution-democratic-republic-congo
“These findings are disappointing, but they give us essential information & reinforce need to identify other candidates for mpox while we continue research on tecovirimat use in other populations with mpox,” said NIAID Director J Marrazzo. “We remain committed to developing interventions, including treatments & vax, that can ease devastating mpox burden in C Africa...
-
Effect of #tecovirimat in human #mpox. This study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using integrative modeling that combines preclinical & clinical data #PLOSBiology https://plos.io/484IfX6
-
#Tecovirimat #Resistance in #Mpox Patients, #USA, 2022–2023, Emerg Infect Dis.: https://wwwnc.cdc.gov/eid/article/29/12/23-1146_article?ACSTrackingID=USCDC_333-DM115592&ACSTrackingLabel=Latest%20Expedited%20Articles%20-%20Emerging%20Infectious%20Diseases%20Journal%20-%20October%2019%2C%202023&deliveryName=USCDC_333-DM115592 #antivirals #drugs #EIDs
-
Gathering real world data on the efficacy of drugs and vaccines used to treat or prevent #monkeypox is vital. Many where developed for #smallpox and approved via the FDA's "animal rule", which means that although the safety data is there, the efficacy is essentially unknown. I wrote a bit about this for #NatureMedicine in September when looking at the use of the #antiviral #tecovirimat for monkeypox.
-
'We report on the protocolized use of tecovirimat (SIGA Technologies), an antiviral drug with activity against orthopoxviruses (including monkeypox and smallpox),1 under an expanded access program for all patients with monkeypox virus (MPXV) disease in Mbaïki, Central African Republic, between December 2021 and February 2022.2 Included in the study were 14 patients in whom MPXV infection had been diagnosed.'
https://www.nejm.org/doi/full/10.1056/NEJMc2210015?query=featured_home